NCT06842992 - A Phase II Study to Evaluate NH102 for Depression | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

December 7, 2025

Study Completion Date

March 10, 2026

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG

NH102

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

DRUG

NH102

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

DRUG

NH102

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

DRUG

Duloxetine Hydrochloride Enteric-coated Capsule

30 mg twice daily for 6 weeks, followed by a 1-week tapering period.

DRUG

Placebo

Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.

Trial Locations (1)

RECRUITING

Shanghai Mental Health Center, Shanghai